Navigation Links
Genomic Health to Announce Second Quarter 2012 Financial Results and Host Conference Call on Wednesday, August 8, 2012
Date:8/1/2012

REDWOOD CITY, Calif., Aug. 1, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, August 8 at 4:30 p.m. Eastern Time to discuss its second quarter 2012 financial results. The call and webcast will follow the release of the second quarter financial results after market close.

Conference Call Details

To access the live conference call on August 8 at 4:30 p.m. Eastern Time via phone, please dial (877) 303-7208 from the United States and Canada or +1(224) 357-2389 internationally.  Please dial in approximately ten minutes prior to the start of the call.  A telephone replay will be available beginning approximately two hours after the call through August 15, and may be accessed by dialing (855) 859-2056 from the United States and Canada or +1(404) 537-3406 internationally.  The replay passcode is 13490376.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's Web site at http://investor.genomichealth.com.  Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global health company that provides actionable genomic information to personalize genomic health decisions.  The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of March 31, 2012, more than 10,000 physicians in over 65 countries had ordered more than 275,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the ability of the company to develop additional tests in the future, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-Q for the quarter ended March 31, 2012. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.  


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
2. Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test
3. Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium to Develop First Antibody Master Set for Epigenetic Studies
4. Gentris Corporation Launches New Pharmacogenomics Services
5. Rubicon Genomics Launches ThruPLEX™ Family of Sample Preparation Products for Next Generation Sequencing Applications
6. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
7. Genomic Health to Announce First Quarter 2012 Financial Results and Host Conference Call on Wednesday, May 2, 2012
8. Empire Genomics Chooses Funakoshi as Japan Distributor
9. Save Up To 25% on International Biotech and Healthcare, and Pharmaceutical Conferences by Registering Through GII
10. Independa, IDEAL LIFE to Provide Plug-and-Play Health Monitoring for Independent Elderly and Their Caregivers
11. GHX WebConnect Fuels Healthcare Efficiency at 2012 Olympics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 4, 2017 The search for ... after a physician/patient consult has long been the goal ... a notable focus of the largest meeting of lab ... to healthcare market research firm Kalorama Information.  The firm ... (POCT) offerings or related supplies and software were at ...
(Date:8/3/2017)... DIEGO , Aug. 3, 2017  Opioid addiction ... diseases driving up healthcare costs and threatening outcomes, were ... lab supply and IVD industry that support them, met ... care market researcher said that drugs of abuse, procalcitonin ... and sessions at the organization,s 69th meeting in ...
(Date:8/2/2017)... BENTON, Ky. , Aug. 2, 2017   Marshall County Hospital in ... team to proactively reduce the risk of hospital-acquired infections (HAIs). The new addition, Tru-D ... UVC light energy to kill deadly pathogens such as C. diff , MRSA, MERS, ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... 2017 , ... “Steve the Snake”: an entertaining and moral-based short story about ... published author, Harold Flash Haskins Jr., a husband, father and grandfather who served as ... “I write moral-based short stories for children and teens. My goal is to teach ...
(Date:8/17/2017)... NC (PRWEB) , ... August 17, 2017 , ... ... dental practice, is adding a new location in Goldsboro, NC to its family ... care that is Riccobene Associates’ trademark starting August 15, 2017. , Riccobene ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... announces that it will feature the National Council for Therapeutic Recreation Certification (NCTRC), ... information. , Established in 1981, NCTRC is a non-profit, international organization dedicated to ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... September 19, 2017 for Anti-Infectives Rx. This off-the-record networking forum of the Boston ... at Harvard Medical School. , Industry leaders and decision makers will discuss issues ...
(Date:8/17/2017)... ... ... Georgia Urology, the largest urology practice in the Southeastern United States, ... East Cobb (4800 Olde Towne Parkway, Suite 220, Marietta). , “Georgia Urology ... Georgia Urology’s managing partner. “She brings a passionate, fresh perspective on general urology to ...
Breaking Medicine News(10 mins):